Multiple Myeloma

Data support prophylactic treatment with tocilizumab as an option to mitigate the risk of CRS for outpatient dosing of teclistamab.

Experts on multiple myeloma discuss how they educate and prepare patients who are going to receive CAR T-cell therapy and provide clinical insights on transitioning patients to community practices following treatment.

A panel of experts on multiple myeloma give an overview of unique challenges in managing adverse effects associated with CAR T-cell therapy as compared with other cancer therapies.

Data from the PERSEUS trial also show that responses deepened over time in both arms among patients with transplant-eligible multiple myeloma.

Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.

Most infection events among those with newly diagnosed multiple myeloma in the MajesTEC-7 trial appeared to occur early during study treatment.

Isatuximab, bortezomib, lenalidomide, and dexamethasone prolonged PFS vs bortezomib, lenalidomide, and dexamethasone, in a subsect of patients with multiple myeloma.

Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.

Similar outcomes were noted when linvoseltamab and teclistamab were analyzed as treatments for patients with relapsed/refractory multiple myeloma.

Data suggest that those with relapsed/refractory multiple myeloma and poor functional status may benefit from talquetamab without increased toxicity.

Eye-related adverse effects after treatment for relapsed/refractory multiple myeloma in DREAMM-7 appear manageable with dose and schedule changes.

Giving tocilizumab before step-up dosing of teclistamab may mitigate cytokine release syndrome in relapsed/refractory multiple myeloma.

Responses occurred in patients with relapsed/refractory multiple myeloma who are refractory to daratumumab but received retreatment with the agent.

Triplet therapies containing belantamab mafodotin may fulfill an unmet need for patients with multiple myeloma following the first relapse.

Surbhi Sidana, MD, provides clinical insights on treatment sequencing strategies for patients with relapsed/refractory multiple myeloma.

Experts on multiple myeloma provide their impressions of the CARTITUDE-4 and KarMMa-3 studies, which led to the approval of cilta-cel and ide-cel in earlier lines of treatment for patients with relapsed/refractory disease.

Myeloma specialists have a comprehensive discussion on CAR T-cell therapy, highlighting treatment selection considerations, adverse event management strategies, unmet needs, and ongoing research.

Myeloma specialists discuss clinical trials investigating CAR T-cell therapies in patients with relapsed/refractory disease.

The FDA has set a Prescription Drug User Fee Act Date of September 27, 2024, for the isatuximab combination in transplant-ineligible NDMM.

Despite increased education on autologous HCT, a lower rate of Black patients with multiple myeloma undergo treatment.

The panel discusses recent updates on bispecific antibodies for patients with relapsed/refractory multiple myeloma, highlighting studies investigating talquetamab, teclistamab, and elranatamab.

Focusing on later lines of therapy for patients with relapsed/refractory multiple myeloma, the panel provides key takeaways on the CARTITUDE-1 and KarMMa trials that investigated cilta-cel and ide-cel.

A panel of experts on multiple myeloma introduce themselves and discuss recent CAR T-cell therapy approvals in earlier treatment lines for patients with relapsed/refractory disease.

Yi Lin, MD, PhD, provides insights on the impact of CAR T-cell therapy on the evolving multiple myeloma treatment landscape.

Advanced practice providers focus on the case of a patient diagnosed with multiple myeloma who lives in a rural area with limited access to care.

Rahul Banerjee, MD, FACP, discusses how the emergence of CAR T-cell therapy has impacted the multiple myeloma treatment landscape by addressing unmet needs and improving patients’ quality of life.

A panel of experts on multiple myeloma discuss the rationale for CAR T-cell therapy, highlighting BCMA as a target and treatment administration practices.

Samer Al'Hadidi, MD, offers advice to community oncologists who treat patients with relapsed/refractory multiple myeloma, and the Oncology Brothers recap the entire discussion.

Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Samer Al'Hadidi, MD, to discuss treatment decision-making strategies for patients with relapsed/refractory multiple myeloma.

In a discussion with the Oncology Brothers on the treatment of patients with relapsed/refractory multiple myeloma, Samer Al'Hadidi, MD, discusses adverse effects associated with CAR T-cell therapy and bispecific antibodies.